Clinical trial
Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza…
NCT00383123 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00383123 |
|---|---|
| Title | Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children |
| Official title | A Phase III, Single-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals') Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Fluarix™, Fluzone |
| Enrollment | 3,327 |
| Start date | Nov 2, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 19, 2007 |
| First posted | Oct 2, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: